Kaposi Sarcoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Kaposi Sarcoma – Pipeline Review, H2 2016’, provides an overview of the Kaposi Sarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kaposi Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma

The report reviews pipeline therapeutics for Kaposi Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Kaposi Sarcoma therapeutics and enlists all their major and minor projects

The report assesses Kaposi Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Kaposi Sarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kaposi Sarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kaposi Sarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aphios Corp

AstraZeneca Plc

Biogenomics Limited

Cannabis Science Inc

Cell Medica Ltd

CytRx Corp

Tumorend LLC

Vironika LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Kaposi Sarcoma Overview 7

Therapeutics Development 8

Pipeline Products for Kaposi Sarcoma - Overview 8

Pipeline Products for Kaposi Sarcoma - Comparative Analysis 9

Kaposi Sarcoma - Therapeutics under Development by Companies 10

Kaposi Sarcoma - Therapeutics under Investigation by Universities/Institutes 11

Kaposi Sarcoma - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Kaposi Sarcoma - Products under Development by Companies 15

Kaposi Sarcoma - Products under Investigation by Universities/Institutes 16

Kaposi Sarcoma - Companies Involved in Therapeutics Development 17

Aphios Corp 17

AstraZeneca Plc 18

Biogenomics Limited 19

Cannabis Science Inc 20

Cell Medica Ltd 21

CytRx Corp 22

Tumorend LLC 23

Vironika LLC 24

Kaposi Sarcoma - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

aldoxorubicin hydrochloride - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

brolucizumab - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

CM-101 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

CSTATI-1 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Dermos - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

doxorubicin - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

interferon alfa-2a - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

interferon alfa-2b - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

selumetinib sulfate - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Small Molecule for Kaposi’s Sarcoma - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Synthetic Peptide to Inhibit HAUSP for Lymphoma and Kaposi Sarcoma - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Kaposi Sarcoma - Dormant Projects 65

Kaposi Sarcoma - Discontinued Products 67

Kaposi Sarcoma - Product Development Milestones 68

Featured News & Press Releases 68

Jun 06, 2016: CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting 68

May 26, 2016: $1.8 Million Fast-Track NIH SBIR Grant for Manocept Immunotherapeutics Evaluation in Kaposi’s Sarcoma Awarded to Navidea 69

May 03, 2016: Navidea and Macrophage Therapeutics to Provide Development Program Update 70

Apr 20, 2016: CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016 71

Sep 03, 2015: Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept Agent in Kaposi’s Sarcoma 72

Jul 02, 2015: Macrophage Therapeutics Reports Data Demonstrating a Manocept Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi’s Sarcoma and Tumor Associated Macrophages 72

Jun 29, 2015: CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 74

May 28, 2015: Delenex Presents Anti-Tumor Activity of DLX1008 75

Jan 20, 2015: CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients 75

Jan 08, 2015: CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma 75

Jan 23, 2014: CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi’s Sarcoma 76

Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I 77

Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma 78

Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma 79

Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1 80

Appendix 81

Methodology 81

Coverage 81

Secondary Research 81

Primary Research 81

Expert Panel Validation 81

Contact Us 81

Disclaimer 82

List of Tables

List of Tables

Number of Products under Development for Kaposi Sarcoma, H2 2016 8

Number of Products under Development for Kaposi Sarcoma – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Comparative Analysis by Unknown Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Kaposi Sarcoma – Pipeline by Aphios Corp, H2 2016 17

Kaposi Sarcoma – Pipeline by AstraZeneca Plc, H2 2016 18

Kaposi Sarcoma – Pipeline by Biogenomics Limited, H2 2016 19

Kaposi Sarcoma – Pipeline by Cannabis Science Inc, H2 2016 20

Kaposi Sarcoma – Pipeline by Cell Medica Ltd, H2 2016 21

Kaposi Sarcoma – Pipeline by CytRx Corp, H2 2016 22

Kaposi Sarcoma – Pipeline by Tumorend LLC, H2 2016 23

Kaposi Sarcoma – Pipeline by Vironika LLC, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Kaposi Sarcoma – Dormant Projects, H2 2016 65

Kaposi Sarcoma – Dormant Projects (Contd..1), H2 2016 66

Kaposi Sarcoma – Discontinued Products, H2 2016 67

List of Figures

List of Figures

Number of Products under Development for Kaposi Sarcoma, H2 2016 8

Number of Products under Development for Kaposi Sarcoma – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Top 10 Targets, H2 2016 26

Number of Products by Stage and Top 10 Targets, H2 2016 26

Number of Products by Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports